Vertex Pharma (VRTX) Tops Q4 EPS by 24c, Revenues Beat; Offers FY19 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex (VRTX) PT Raised to $234 at BMO Capital
February 6, 2019 7:53 AM ESTBMO Capital analyst Do Kim raised the price target on Vertex (NASDAQ: VRTX) to $234.00 (from $192.00) while maintaining a Outperform rating.
Kim commented, "Our target price rises to $234 from $192, as we increase long-term CF revenue projections, following another solid 4Q18 beat on revenues and... More
Vertex (VRTX) PT Raised to $220 at Cowen
February 6, 2019 7:52 AM ESTCowen analyst Phil Nadeau raised the price target on Vertex (NASDAQ: VRTX) to $220.00 (from $210.00) while maintaining a Outperform rating.
The analyst commented, "VRTX reported Q4 CF franchise revenue of $868.2MM vs consensus of $818.8MM, non-GAAP EPS of $1.30 vs. consensus of $1.08. 2019 revenue guidance... More
Maxim Group Downgrades Vertex (VRTX) to Hold
February 6, 2019 7:45 AM ESTMaxim Group analyst Jason McCarthy downgraded Vertex (NASDAQ: VRTX) from Buy to Hold.
The analyst highlighted:
Vertex reported 4Q18 with cystic fibrosis (CF) revenue of $868M, representing sequential growth of 11% and beating consensus of $816M; the results include Kalydeco revenue of $259M vs. $250.5M... MoreVertex (VRTX) PT Lowered to $213 at RBC Capital
February 6, 2019 7:14 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Vertex (NASDAQ: VRTX) to $213.00 (from $215.00) while maintaining a Outperform rating.
... MoreJefferies Not Concerned About 'Crown Use' of Vertex's (VRTX) Orkambi
February 1, 2019 8:27 AM ESTJefferies analyst Michael Yee reiterated a Buy rating and $210 price target on Vertex (NASDAQ: VRTX) noting that on Feb 4th, the UK Parliament House of Commons is scheduled to debate whether the government should enact a "Crown Use" license rule that allows... More
